Keywords: further, biotech, acquisition, akzo, nobel, diosynth, business

Further biotech acquisition for Akzo Nobel

Article | 24 April 2001

Akzo Nobel's Diosynth business unit, which produces activepharmaceutical ingredients, is to acquire the US firm Covance Biotechnology Services for $190 million. ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Akzo Nobel

Go to company listing

Related Drugs

E.E.S.

Erythromycin Ethylsuccinate

Go to drug listing